sues, we solved the structure of full-length E. coli Rho in complex with BCM, FPDB, and FB. Our data show In the cell, BCM attenuates the ability of Rho to reach and dissociate the RNA polymerase from its DNA temthat the antibiotic binds at a pocket located at the interface between adjacent C-terminal domains that is plate, yielding unnaturally long RNA transcripts (Magyar et al., 1996; Zwiefka et al., 1993 lead to a slight contraction of the hexamer. As a consequence, the "A" and "F" protomers at the opening of (Tables 1 and 2 Figure 5A ). These mutations include subpoorly ordered, their juxtaposition is consistent with stitutions at Ser266, Gly337, Met219, and Leu208. All of NaBH 4 crosslinking data (Vincent et al., 2000a) . In the these lie within or near the BCM binding pocket and case of FB, which contains a formyl group appended are also adjacent to the ATP and secondary RNA bindto the C(5a) double bond, the inhibitor makes only one ing sites. additional interaction with Rho, hydrogen bonding diIn Rho functional assays, the three mutants Ser264-rectly to Lys336# of the protomer adjacent to the ATP Cys, Ser266Ala, and Leu208Arg were found to be highly binding site (Figures 3C and 4B ). This configuration resistant to BCM inhibition, suggesting that these resilikewise agrees with prior crosslinking studies (Riba et  al., 1998) .
dues may directly interact with BCM (Magyar et al., Figure 5A ). This amino acid is, however, part of the hydrophobic core of the ATP binding domain and is lomutants increase the affinity of Rho for ssRNA, suggesting that their mild resistance to BCM could result cated adjacent to Glu211 and Arg212, two residues that directly contact BCM (Figure 4) . Introduction of a large from a diminished capacity of the drug to displace RNA Hg et al., 1996a) . Our work accounts for this ob- 
